What the study found
A major study suggested that glucosamine, a popular supplement for joint pain, could be linked to faster progression from mild cognitive impairment to dementia. The finding was reported by ScienceDaily based on a research publication.
This is an observational finding, not a randomized trial. Observational studies cannot establish causation. People who take glucosamine may differ from people who don't in ways that also affect cognitive health: they may be older, have more joint problems, be less physically active, or have different dietary patterns.
One observational study does not prove glucosamine causes cognitive decline. But it raises a signal worth watching for a supplement taken by millions of older adults.
Why this matters
Glucosamine is one of the most widely used supplements in the world, particularly among older adults. Older adults are also the population most at risk for cognitive decline. If the association holds in further research, it would represent a case where a supplement marketed for one benefit (joint health) may carry an unrelated risk (cognitive).
The mechanism is unclear. Glucosamine is an amino sugar involved in cartilage formation. There is no obvious biological pathway connecting glucosamine to cognitive decline. The association could be driven by confounding, chance, or an as-yet-unidentified mechanism.
What to do
- Do not stop taking glucosamine based on one observational study. Talk to your doctor if you are concerned.
- If you have joint pain and cognitive concerns, discuss alternatives with your physician, including physical therapy, weight management, and other joint supplements.
- Watch for replication. A single observational study is a signal, not evidence. If independent cohorts show the same association, the signal strengthens.